New drug aims to curb hunger in Prader-Willi syndrome

NCT ID NCT06772597

Ongoing Disease control Sponsor: Rhythm Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests setmelanotide (Imcivree), a daily injection, in 18 people aged 6 to 65 with Prader-Willi syndrome who have obesity. The study will check if the drug is safe and helps reduce body weight and hunger over 52 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: setmelanotide (Imcivree), a daily injection
What this could lead to: If it works, this could point toward a treatment that helps control appetite and weight in people with Prader-Willi syndrome.
What could go wrong: This is a small, early-phase trial with only 18 participants, so results may not apply to everyone. The drug requires daily injections and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERPHAGIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hyperphagia Obesity obesity disorder Prader-Willi syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERPHAGIA OBESITY PRADER-WILLI SYNDROME

Contacts and locations

Locations

University of Florida

Gainesville, Florida, 32610-0296, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.